Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beenu Thakral

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Annals of Diagnostic Pathology|September 25, 2020
Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphomaKirill A Lyapichev, Ali Sakhdari, Joseph D Khoury, et al.
Cancer Medicine|December 6, 2019
RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVADAli Sakhdari, Beenu Thakral, Sanam Loghavi, et al.
Archives of Pathology & Laboratory Medicine|June 16, 2025
Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient CohortSa A Wang, Shaoying Li, Wei Wang, et al.
Human Pathology|October 16, 2022
Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasmsLianqun Qiu, Okechukwu V Nwogbo, L Jeffrey Medeiros, et al.
Leukemia & Lymphoma|September 20, 2019
<i>De novo</i> CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab eraBei Hu, Loretta J Nastoupil, Sanam Loghavi, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2024
Expression of CD6 in Aggressive NK/T-cell Neoplasms and Assessment as a Potential Therapeutic Target: A Bone Marrow Pathology Group StudyXiaoxian Zhao, Chad M McCall, Jared G Block, et al.
Archives of Pathology & Laboratory Medicine|December 23, 2024
The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic SyndromesFnu Sameeta, Wei Wang, Fatima Zahra Jelloul, et al.
Frontiers in Oncology|November 16, 2020
Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
Blood Cancer Journal|August 28, 2020
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different featuresWen Shuai, Pei Lin, Paolo Strati, et al.
The American Journal of Surgical Pathology|July 25, 2022
MUM1/IRF4 is Highly Expressed in Dermatopathic Lymphadenopathy: Potential Utility in Diagnosis and Differential DiagnosisSofia Garces, Zbigniew Rudzki, C Cameron Yin, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Annals of Diagnostic Pathology|September 25, 2020
Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphomaKirill A Lyapichev, Ali Sakhdari, Joseph D Khoury, et al.
Cancer Medicine|December 6, 2019
RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVADAli Sakhdari, Beenu Thakral, Sanam Loghavi, et al.
Archives of Pathology & Laboratory Medicine|June 16, 2025
Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient CohortSa A Wang, Shaoying Li, Wei Wang, et al.
Human Pathology|October 16, 2022
Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasmsLianqun Qiu, Okechukwu V Nwogbo, L Jeffrey Medeiros, et al.
Leukemia & Lymphoma|September 20, 2019
<i>De novo</i> CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab eraBei Hu, Loretta J Nastoupil, Sanam Loghavi, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2024
Expression of CD6 in Aggressive NK/T-cell Neoplasms and Assessment as a Potential Therapeutic Target: A Bone Marrow Pathology Group StudyXiaoxian Zhao, Chad M McCall, Jared G Block, et al.
Archives of Pathology & Laboratory Medicine|December 23, 2024
The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic SyndromesFnu Sameeta, Wei Wang, Fatima Zahra Jelloul, et al.
Frontiers in Oncology|November 16, 2020
Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
Blood Cancer Journal|August 28, 2020
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different featuresWen Shuai, Pei Lin, Paolo Strati, et al.
The American Journal of Surgical Pathology|July 25, 2022
MUM1/IRF4 is Highly Expressed in Dermatopathic Lymphadenopathy: Potential Utility in Diagnosis and Differential DiagnosisSofia Garces, Zbigniew Rudzki, C Cameron Yin, et al.
Pageof 10